Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I

Ruxolitinib provided clinical benefit for patients with myelofibrosis in clinical trials. However, assessing benefit in community settings remains challenging. This exploratory analysis evaluated results from the phase 3 COMFORT-I trial using practical measures (N=286). Spleen length alone was insufficient for identifying all patients receiving clinical benefit, emphasizing the importance of using multiple myelofibrosis assessment methods in the community setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research